Screening drug target combinations in disease-related molecular networks

Abstract

Background For treating a complex disease such as cancer, some effective means are needed to control biological networks that underlies the disease. The one-target one-drug paradigm has been the dominating drug discovery approach in the past decades. Compared to single target-based drugs, combination drug targets may overcome many limitations of single drug target and achieve a more effective and safer control of the disease. Most of existing combination drug targets are developed based on clinical experience or text-and-trial strategy, which cannot provide theoretical guidelines for designing and screening effective drug combinations. Therefore, systematic identification of multiple drug targets and optimal intervention strategy needs to be developed. Results We developed a strategy to screen the synergistic combinations of two drug targets in disease networks based on the classification of single drug targets. The method tried to identify the sensitivity of single intervention and then the combination of multiple interventions that can restore the disease network to a desired normal state. In our strategy of screening drug target combinations, we first classified all drug targets into sensitive and insensitive single drug targets. Then, we identified the synergistic and antagonistic of drug target combinations, including the combinations of sensitive drug targets, the combinations of insensitive drug target and the combination of sensitive and insensitive targets. Finally, we applied our strategy to Arachidonic Acid (AA) metabolic network and found 18 pairs of synergistic drug target combinations, five of which have been proven to be viable by biological or medical experiments. Conclusions Different from traditional methods for judging drug synergy and antagonism, we propose the framework of how to enhance the efficiency by perturbing two sensitive targets in a combinatorial way, how to decrease the drug dose and therefore its side effect and cost by perturbing combinatorially a main sensitive target and an auxiliary insensitive target, and how to perturb two insensitive targets to realize the transition from a disease state to a healthy one which cannot be realized by perturbing each insensitive target alone. Although the idea is mainly applied to an AA metabolic network, the strategy holds for more general molecular networks such as combinatorial regulation in gene regulatory networks. Electronic supplementary material The online version of this article (10.1186/s12859-019-2730-8) contains supplementary material, which is available to authorized users.

Diversified strategy for the synthesis of DNA-encoded oxindole libraries

“…The advances in molecular biology, in particular genomic sciences, has had a deep impact on the identification of potential disease-related protein targets in drug discovery. 1 Medicinal chemistry programs mostly rely on screening compound collections populated by a range of molecules derived from a set of known and robust chemical reactions. Based on the comprehensive analysis conducted by Dean G. Brown, high-throughput screening dominates early drug discovery, in conjunction with fragment-based screening and knowledge directed screens.…”

Histopathological changes in Oreochromis mossambicus (Peters, 1852) ovaries after a chronic exposure to a mixture of the HIV drug nevirapine and the antibiotics sulfamethoxazole and trimethoprim

“…The multi-drug combination is used in complex diseases such as HIV, TB, cancers and other complicated diseases which do not follow the original one-target one-drug concept ( National Department of Health 2015 ; Panel on Opportunistic Infections in Adults and Adolescents with HIV, 2019 ). For these complex diseases, the combination of drugs targeting the different sites of the disease network in the body is needed for better results ( Luo et al., 2019 ; Yuan and Chen 2019 ). The choice of the drugs to combine in a prescription is done very carefully to avoid the risk of toxicity due to drugs interactions ( Luo et al., 2019 ; Yuan and Chen 2019 ).…”

“…For these complex diseases, the combination of drugs targeting the different sites of the disease network in the body is needed for better results ( Luo et al., 2019 ; Yuan and Chen 2019 ). The choice of the drugs to combine in a prescription is done very carefully to avoid the risk of toxicity due to drugs interactions ( Luo et al., 2019 ; Yuan and Chen 2019 ). For aquatic animals which are unintentionally exposed to the mixtures of different types of pharmaceuticals present in surface waters their whole life, there is concerns that those drugs interactions may have greater negative effects on their health than a single drug exposure could cause ( Schoenfuss et al., 2016 ; Mezzelani et al., 2018 ).…”

Potential Anti-Proliferative, Anti-Inflammatory and Anti-Viral Components from Sinopodophyllum Hexandrum Explored Using Bio-Affinity Ultrafiltration with Multiple Drug Targets

“…For multi-causal diseases regulated by complicated pharmacological networks, singletarget remedies rapidly develop resistance, bring about poor clinical therapeutic effects, and eventually lead to treatment failure on the basis of the strategy of "one disease-one target-one therapeutic drug" [8]. In response to the limitations of single-target drugs, the development of multi-target natural agents, especially with synergistic effects, will provide greater bene ts in enhancing e cacy and lowering drug resistance [9]. Additionally, nearly half of small molecule drugs were developed as enzyme inhibitors according to current statistics.…”